Lunit and Agilent Partner to Develop AI-Powered Companion Diagnostics

Lunit, a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc., a global leader in life sciences and diagnostics, announced Sunday a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The partnership aims to revolutionize biomarker testing by combining Lunit's artificial intelligence technology with Agilent's expertise in tissue-based companion diagnostics to create advanced solutions addressing the demands of novel and complex biomarker assays in drug development.

Under the agreement, the companies will develop AI-powered companion diagnostic tools designed to enhance diagnostic accuracy and therapeutic efficacy measurement. The initial focus will leverage Lunit's AI algorithms alongside Agilent's state-of-the-art assays to evaluate biomarkers critical for developing new pharmaceutical therapies. These joint solutions will support pharmaceutical companies in companion diagnostic product development, improving the precision and accuracy of biomarker testing while ultimately providing patients with more tailored treatment options.

"Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation," said Brandon Suh, CEO of Lunit. "By combining Agilent's global leadership in tissue-based diagnostics with Lunit's proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence - ultimately ensuring patients receive the right treatment at the right time."

The collaboration addresses a critical challenge in precision oncology where manual interpretation of biomarker testing remains the standard despite technological advances. By automating and enhancing this process through artificial intelligence, the partnership seeks to accelerate the development timeline for biomarker-driven therapies while improving confidence in diagnostic results.

"Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today," said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division at Agilent. "Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide."

The collaboration will initially concentrate on co-developing AI-powered assays for use in research and clinical trials. This strategic focus allows both companies to refine their integrated approach before broader implementation, ensuring the solutions meet the rigorous standards required for pharmaceutical development and patient care. The agreement represents a significant step forward for both companies as they work to redefine artificial intelligence's role in precision oncology and translational medicine.